We have read the interesting paper by Costa and Saxena entitled ''Surgical chylothorax in neonates: management and outcomes", recently published in the World Journal of Pediatrics [1] . There are few points of the article that we would like to discuss. We recently published a systematic review focusing on the use of octreotide for congenital and acquired chylothorax in newborns [2] . Our review concluded that octreotide was safe and effective in the treatment of chylothorax in newborns, especially for the congenital forms, and that octreotide therapy should be considered as an adjunctive treatment in term and preterm neonates affected by congenital and acquired chylothorax. Costa and Saxena reported 12 further cases of acquired (post-surgical) chylothorax than those included in our review. It is reassuring that both articles [1, 2] obtained similar conclusions. The initial dose of octreotide varied from 0.5 to 10 μg/kg/h [1] and from 0.3 to 15 μg/kg/h [2], and the maximum dose reported was 10 vs 7.5 μg/kg/h, respectively [1, 2] . Apart from slight dose differences, in our opinion lacking practical clinical meaning, what we consider very important is that both reviews [1, 2] concluded that octreotide treatment is safe and effective and that the observed (scarce) adverse effects are mild and transient and generally well tolerated and not requiring discontinuation of the treatment.
To the Editor,
We have read the interesting paper by Costa and Saxena entitled ''Surgical chylothorax in neonates: management and outcomes", recently published in the World Journal of Pediatrics [1] . There are few points of the article that we would like to discuss. We recently published a systematic review focusing on the use of octreotide for congenital and acquired chylothorax in newborns [2] . Our review concluded that octreotide was safe and effective in the treatment of chylothorax in newborns, especially for the congenital forms, and that octreotide therapy should be considered as an adjunctive treatment in term and preterm neonates affected by congenital and acquired chylothorax. Costa and Saxena reported 12 further cases of acquired (post-surgical) chylothorax than those included in our review. It is reassuring that both articles [1, 2] obtained similar conclusions. The initial dose of octreotide varied from 0.5 to 10 μg/kg/h [1] and from 0.3 to 15 μg/kg/h [2] , and the maximum dose reported was 10 vs 7.5 μg/kg/h, respectively [1, 2] . Apart from slight dose differences, in our opinion lacking practical clinical meaning, what we consider very important is that both reviews [1, 2] concluded that octreotide treatment is safe and effective and that the observed (scarce) adverse effects are mild and transient and generally well tolerated and not requiring discontinuation of the treatment.
We, as certainly Costa and Saxena, are aware that given the very low incidence and the heterogeneity of chylothorax in neonates, randomized controlled trials to clarify octreotide use appear to be quite unfeasible, even in multicentric settings. Thus, we feel that reporting cases of neonatal chylothorax should be encouraged. Two independent large reviews including a wide number of patients have agreed that the conclusions show the use of octreotide to be the best available tool for the treatment of chylothorax in the neonatal age.
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